Clinical trials: Hypertrophic Cardiomyopathies
Cardiomegaly, Noonan Syndrome
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
- Trial name
- MEKinRAS (NCT06555237)
- Testing
- Trametinib tablet, Standard therapy
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Lumbar Spinal Stenosis, Cardiac Amyloidosis
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Primary objective: To identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.
- Conditions
- Lumbar Spinal Stenosis, Cardiac Amyloidosis, ATTR Amyloidosis Wild Type, ATTR Gene Mutation
- Trial name
- NCT06034405
- Testing
- Tc99-PYP or Tc99-HDMP Scan
- Where
- 6 sites in United States
- Volunteers
- 1,663 people, healthy volunteers welcome
- Sponsor
- Columbia University
Heart Failure
Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart Failure
The purpose of this study is to examine the safety and potential effectiveness of a new surgical procedure for treating heart failure.
- Trial name
- RECOVER (NCT00881777)
- Testing
- Radiofrequency heating of the myocardial infarct scar, Coronary Artery Bypass Grafting (CABG) surgery
- Where
- 3 sites in Paraguay, Poland
- Volunteers
- 3 people
- Sponsor
- CoRepair, Inc.
Hypertrophic Cardiomyopathy
Role of Perhexiline in Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart muscle condition affecting up to 1 in 200 of the general population.
- Trial name
- RESOLVE-HCM (NCT04426578)
- Testing
- Perhexiline
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- Flinders University
Cardiomyopathy, Hypertrophic Obstructive
IMPACT-CMH: Impact of Mitral Valve and Subvalvular Abnormalities in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten
The objective of this observational study is to evaluate the association between the presence of mitral valvular and/or subvalvular anatomical abnormalities prior to initiation of mavacamten and the hemodynamic response at 6…
- Trial name
- IMPACT-CMH (NCT07716826)
- Volunteers
- 150 people
- Sponsor
- French Cardiology Society
Hypertrophic Cardiomyopathy, Heart Failure
Empagliflozin in Hypertrophic Cardiomyopathy
The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study.
- Trial name
- EMPA-REPAIR (NCT05182658)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Poland
- Volunteers
- 250 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
Mavacamtenis a novel, small molecule, selective allosteric inhibitor of cardiac-specific myosin, for the treatment of patients with symptomatic oHCM.
- Trial name
- NCT05174416
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 81 people
- Sponsor
- LianBio LLC
Heart Failure, Cardiac Imaging Techniques
MRI to Predict Rejection and Failure in Transplant and Cardiomyopathy Patients
Overall Research Strategy of this protocol is to refine and validate noninvasive CMR imaging sequences with invasive hemodynamic and pathology results to create a comprehensive, noninvasive, radiation-reduced regimen for…
- Conditions
- Heart Failure, Cardiac Imaging Techniques, Congenital Heart Defects
- Trial name
- NCT03822442
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Children's National Research Institute
Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy, Obstructive
Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric hypertrophy of the heart in absence of loading conditions like hypertension.
- Trial name
- FUSION-HCM (NCT06400524)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Amsterdam UMC, location VUmc
Left Ventricular Non-compaction Cardiomyopathy, Left Ventricular Failure
Value of Cardiac Magnetic Resonance (CMR) Derived Parameters for Diagnosing Left Ventricular Non-compaction Cardiomyopathy
Left ventricular non-compaction (LVNC) is a rare cardiomyopathy characterized by numerous excessively prominent left ventricular (LV) trabeculation and deep intertrabecular recesses communicating with the ventricular cavity and…
- Conditions
- Left Ventricular Non-compaction Cardiomyopathy, Left Ventricular Failure, Left Ventricular Hypertrophy
- Trial name
- NCT01481298
- Where
- Germany
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Leipzig
Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance.
- Trial name
- NCT05135871
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- LianBio LLC
Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular…
- Conditions
- Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies
- Trial name
- IMPROVE-NICM (NCT06730464)
- Where
- 4 sites in Italy, Portugal and 1 more
- Volunteers
- 500 people
- Sponsor
- Centro Medico Teknon
Hypertrophic Cardiomyopathy
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects.
- Trial name
- NCT02329184
- Testing
- MYK-461
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- MyoKardia, Inc.
Obstructive Hypertrophic Cardiomyopathy
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
- Trial name
- CAMELLIA-HCM (NCT07023341)
- Testing
- BAY3723113
- Where
- 23 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Bayer
Healthy Participants
A Study to Evaluate the Effects of Mavacamten in Healthy Participants
The purpose of the study is to evaluate the effect between two different single doses of mavamten in healthy participants.
- Trial name
- NCT05719805
- Testing
- Mavacamten
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?
Aims and objectives: The primary objective of this study is to assess whether a structured exercise program improves cardiac relaxing properties in patients with hypertrophic cardiomyopathy (HCM).
- Trial name
- WEDGE-HCM (NCT03537183)
- Testing
- Exercise training
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Bispebjerg Hospital
Obstructive Hypertrophic Cardiomyopathy, Healthy Adult Subjects
Safety, Tolerability and Pharmacokinetics Study of CK-3773274
The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in Chinese healthy adult subjects. 2.
- Trial name
- NCT04783766
- Testing
- CK-3773274
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Corxel Pharmaceuticals
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- CEDAR-HCM (NCT06412666)
- Testing
- Aficamten
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 65 people
- Sponsor
- Cytokinetics
Cardiomyopathy, Hypertrophic, Familial
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease
Genetically inherited heart diseases (familial cardiomyopathies) are conditions affecting the heart passed on to family members through abnormalities in genetic information.
- Trial name
- NCT00001881
- Where
- United States
- Volunteers
- 9,999 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertrophic Cardiomyopathy
Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...
Several studies have shown that specialized pacemaking devices (DDD pacing) can improve the symptoms associated with hypertrophic cardiomyopathy (HCM) in adults.
- Trial name
- NCT00001396
- Testing
- Paragon Pacemaker
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)